Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1986 Sep;78(3):807-14.
doi: 10.1172/JCI112644.

Role of insulin and glucagon in the response of glucose and alanine kinetics in burn-injured patients

Role of insulin and glucagon in the response of glucose and alanine kinetics in burn-injured patients

F Jahoor et al. J Clin Invest. 1986 Sep.

Abstract

We investigated the roles of insulin and glucagon as mediators of changes in glucose and alanine kinetics during the hypermetabolic response to injury in 10 burn patients by infusing somatostatin with and without insulin replacement. Glucose and alanine kinetics were measured by primed-constant infusions of 6,6-d2-glucose and [3-13C]alanine. The basal rate of glucose production and alanine flux were significantly elevated in all patients. Lowering both hormones simultaneously caused an insignificant reduction in glucose production, but plasma glucose rose significantly (P less than 0.01), because of reduced clearance. Alanine flux and total plasma amino nitrogen increased significantly (P less than 0.05) above basal. Selectively lowering glucagon concentration decreased glucose production (P less than 0.05), and exogenous glucose was infused to maintain euglycemia. Alanine flux and total plasma amino nitrogen remained unchanged. In severely burned patients hyperglucagonemia stimulates increased glucose production, basal insulin suppression glucose production, stimulates basal glucose clearance, and is important for regulation of plasma amino acid concentrations, and the selective lowering of glucagon while maintaining basal insulin constant normalized glucose kinetics.

PubMed Disclaimer

References

    1. J Clin Invest. 1969 Dec;48(12):2273-82 - PubMed
    1. Ann N Y Acad Sci. 1959 Sep 25;82:420-30 - PubMed
    1. Lancet. 1971 Apr 17;1(7703):767-9 - PubMed
    1. J Clin Invest. 1971 Aug;50(8):1702-11 - PubMed
    1. Diabetes. 1971 Dec;20(12):834-8 - PubMed

Publication types